PL355852A1 - Fragmenty białka wirusowego 2 lub 3 wirusa poliomy jako nośniki do substancji aktywnych - Google Patents
Fragmenty białka wirusowego 2 lub 3 wirusa poliomy jako nośniki do substancji aktywnychInfo
- Publication number
- PL355852A1 PL355852A1 PL00355852A PL35585200A PL355852A1 PL 355852 A1 PL355852 A1 PL 355852A1 PL 00355852 A PL00355852 A PL 00355852A PL 35585200 A PL35585200 A PL 35585200A PL 355852 A1 PL355852 A1 PL 355852A1
- Authority
- PL
- Poland
- Prior art keywords
- virus
- fragments
- active ingredients
- polyoma
- transporting active
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyamides (AREA)
- Medicinal Preparation (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19916224A DE19916224C1 (de) | 1999-04-10 | 1999-04-10 | Synthetisches biologisch aktives Molekül |
| PCT/DE2000/000976 WO2000061616A1 (de) | 1999-04-10 | 2000-04-03 | Fragmente des virus proteins 2 oder 3 des polymavirus als fähren für wirkstoffe |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL355852A1 true PL355852A1 (pl) | 2004-05-31 |
Family
ID=7904139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00355852A PL355852A1 (pl) | 1999-04-10 | 2000-04-03 | Fragmenty białka wirusowego 2 lub 3 wirusa poliomy jako nośniki do substancji aktywnych |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7011968B1 (pl) |
| EP (2) | EP1173475B1 (pl) |
| JP (1) | JP2002544122A (pl) |
| KR (1) | KR100627935B1 (pl) |
| CN (1) | CN1346366A (pl) |
| AT (1) | ATE303401T1 (pl) |
| AU (1) | AU768669B2 (pl) |
| BR (1) | BR0011178A (pl) |
| CA (1) | CA2364536A1 (pl) |
| CZ (1) | CZ20013621A3 (pl) |
| DE (3) | DE19916224C1 (pl) |
| EA (1) | EA006631B1 (pl) |
| HU (1) | HUP0200679A2 (pl) |
| IL (1) | IL145403A0 (pl) |
| MX (1) | MXPA01010189A (pl) |
| NO (1) | NO20014891L (pl) |
| PL (1) | PL355852A1 (pl) |
| WO (1) | WO2000061616A1 (pl) |
| ZA (1) | ZA200107658B (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19916224C1 (de) * | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
| GB2357084A (en) * | 1999-12-06 | 2001-06-13 | Amersham Pharm Biotech Uk Ltd | A hydrophobic carrier peptide |
| DE10306789A1 (de) * | 2003-02-18 | 2004-08-26 | Responsif Gmbh | Zusammensetzung zur Verabreichung an ein Lebewesen und Verfahren zur Markierung von Mitteln |
| US20090062237A1 (en) * | 2007-06-15 | 2009-03-05 | Mayo Foundation For Medical Education And Research | Evaluating immune competence |
| EP2636746A1 (en) | 2012-03-06 | 2013-09-11 | Life Science Inkubator | A novel drug delivery system based on JCV-VLP |
| CN113278634B (zh) * | 2020-11-16 | 2022-06-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
| US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
| GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| NZ255831A (en) * | 1992-08-21 | 1997-04-24 | Biogen Inc | Fusion proteins comprising biologically active cargo moiety and transport peptides from the hiv tat protein, their preparation and use |
| US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
| DE4335025A1 (de) | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
| DE19543553B4 (de) | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
| DE19618797C2 (de) * | 1996-05-10 | 2000-03-23 | Bertling Wolf | Vehikel zum Transport molekularer Substanz |
| US5858648A (en) * | 1996-11-04 | 1999-01-12 | Sienna Biotech, Inc. | Assays using reference microparticles |
| DE19916224C1 (de) * | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
-
1999
- 1999-04-10 DE DE19916224A patent/DE19916224C1/de not_active Expired - Fee Related
-
2000
- 2000-04-03 CA CA002364536A patent/CA2364536A1/en not_active Abandoned
- 2000-04-03 DE DE10080849T patent/DE10080849D2/de not_active Expired - Fee Related
- 2000-04-03 HU HU0200679A patent/HUP0200679A2/hu unknown
- 2000-04-03 EP EP00922458A patent/EP1173475B1/de not_active Expired - Lifetime
- 2000-04-03 JP JP2000611557A patent/JP2002544122A/ja active Pending
- 2000-04-03 US US09/958,451 patent/US7011968B1/en not_active Expired - Fee Related
- 2000-04-03 AU AU42850/00A patent/AU768669B2/en not_active Ceased
- 2000-04-03 MX MXPA01010189A patent/MXPA01010189A/es unknown
- 2000-04-03 EP EP05009073A patent/EP1586582A1/de not_active Withdrawn
- 2000-04-03 IL IL14540300A patent/IL145403A0/xx unknown
- 2000-04-03 BR BR0011178-3A patent/BR0011178A/pt not_active Application Discontinuation
- 2000-04-03 AT AT00922458T patent/ATE303401T1/de not_active IP Right Cessation
- 2000-04-03 CN CN00806109A patent/CN1346366A/zh active Pending
- 2000-04-03 KR KR1020017012890A patent/KR100627935B1/ko not_active IP Right Cessation
- 2000-04-03 PL PL00355852A patent/PL355852A1/pl not_active Application Discontinuation
- 2000-04-03 CZ CZ20013621A patent/CZ20013621A3/cs unknown
- 2000-04-03 WO PCT/DE2000/000976 patent/WO2000061616A1/de active IP Right Grant
- 2000-04-03 DE DE50011068T patent/DE50011068D1/de not_active Expired - Fee Related
- 2000-04-03 EA EA200101066A patent/EA006631B1/ru not_active IP Right Cessation
-
2001
- 2001-09-18 ZA ZA200107658A patent/ZA200107658B/en unknown
- 2001-10-08 NO NO20014891A patent/NO20014891L/no not_active Application Discontinuation
-
2005
- 2005-12-22 US US11/316,467 patent/US20070009921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1173475B1 (de) | 2005-08-31 |
| IL145403A0 (en) | 2002-06-30 |
| KR20020007361A (ko) | 2002-01-26 |
| AU4285000A (en) | 2000-11-14 |
| CA2364536A1 (en) | 2000-10-19 |
| CZ20013621A3 (cs) | 2002-05-15 |
| ZA200107658B (en) | 2002-07-22 |
| JP2002544122A (ja) | 2002-12-24 |
| EA006631B1 (ru) | 2006-02-24 |
| AU768669B2 (en) | 2003-12-18 |
| HUP0200679A2 (en) | 2002-06-29 |
| ATE303401T1 (de) | 2005-09-15 |
| DE50011068D1 (de) | 2005-10-06 |
| KR100627935B1 (ko) | 2006-09-22 |
| EP1586582A1 (de) | 2005-10-19 |
| US20070009921A1 (en) | 2007-01-11 |
| EA200101066A1 (ru) | 2002-04-25 |
| US7011968B1 (en) | 2006-03-14 |
| NO20014891D0 (no) | 2001-10-08 |
| DE10080849D2 (de) | 2002-06-27 |
| MXPA01010189A (es) | 2003-07-21 |
| BR0011178A (pt) | 2002-05-21 |
| EP1173475A1 (de) | 2002-01-23 |
| CN1346366A (zh) | 2002-04-24 |
| NO20014891L (no) | 2001-11-07 |
| WO2000061616A1 (de) | 2000-10-19 |
| DE19916224C1 (de) | 2000-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1021824A1 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
| UA43348C2 (uk) | Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад | |
| IL123514A0 (en) | Antagonists of the oncogenic activity of the protein MDM2 and use thereof in the treatment of cancers | |
| TR199802789T2 (xx) | Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar. | |
| TR199802534T2 (xx) | Leptin (OB Protein) fragmanlar� | |
| BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
| WO2000002916A3 (en) | PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY | |
| AU4363199A (en) | Use of hmg proteins for the preparation of medicaments having cytotoxic activity | |
| PL355852A1 (pl) | Fragmenty białka wirusowego 2 lub 3 wirusa poliomy jako nośniki do substancji aktywnych | |
| NO970325L (no) | Fremgangsmåte for fremstilling av biologisk aktivt dimerisk protein | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| DK1165102T3 (da) | Matrixproteinpræparater til podning i ikke-mineraliseret væv | |
| HUP0102975A2 (hu) | Kemotaxis-gátló Staphylococcus protein (CHIPS) és annak alkalmazása | |
| EP1174439A3 (en) | Compositions and methods for treating infections using analogues of indolicidin | |
| FR2766489B1 (fr) | Derives de streptogramines, leur preparation et les compositions qui les contiennent | |
| DE59509948D1 (de) | Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein | |
| ATE282704T1 (de) | Isolierte und gereinigte humane lösliche guanylylcyclase alpha1/beta1 (hsgc alpha1/beta1) | |
| KR920700224A (ko) | 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제 | |
| RU97102207A (ru) | Белок мутантного человеческого гормона роста, дезоксирибонуклеотид, экспрессионная плазмида, продукт экспрессии, антитело, лекарственные средства | |
| MX9604539A (es) | Aminoacidos modificados para la distribucion de farmaco. | |
| TH40967A (th) | บีตา-ไลโพ โปรตีนและการใช้งานของมัน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |